
Plan of Research on Sodium Intake in Diabetic Patients in Korea

Jung Eun Lee Sookmyung Women's University

Contents

- Significance of Research on Sodium Intake
- Study Design and Potential Research Design
- Issues to Consider
- Future Direction

조선일보 2011.04.19




외식 잦은 30~40대 직장인들 '나트륨 비상'

가장 큰 이유는? 직장인들 두끼 이상 외식 식당은 맛 살리려 소금 과용


나트륨 섭취량 세계 최고수준… WHO 권장량의 3배

당뇨병과 당뇨합병증 환자 증가 추이




출처 : 국민건강보험공단

Sodium Excretion from 24-hour urine



Brown IJ 2009; Son SM 2007

Trends in Sodium Intake among Koreans 1998-2010 NHANES




Food Sources Contributing to Na Intake

	1998		200)1	200	5	200)7	200)8	200	09	201	LO
순 위	음식군	%	음식군	%	음식군	%	음식군	%	음식군	%	음식군	%	음식군	%
1	김치	31.7	김치	28.3	김치	23.7	김치	26.6	김치	25.2	김치	24.3	김치	22.8
2	국/탕	13.4	국/탕	13.8	면/ 만두	13.8	면/ 만두	13.0	면/ 만두	12.2	면/ 만두	12.9	면/ 만두	12.4
3	면/ 만두	10.5	찌개/ 전골	11.2	국/탕	12.6	국/탕	10.2	국/탕	10.2	국/탕	10.7	국/탕	10.7
4	찌개/ 전골	8.8	면/ 만두	11.1	찌개/전 골	9.2	찌개/ 전골	8.5	찌개/ 전골	8.7	찌개/ 전골	8.8	찌개/전 골	8.6
5	볶음	4.9	밥	5.3	밥	6.4	밥	5.5	밥	6.4	밥	5.8	밥	5.5
6	구이	3.7	볶음	4.5	볶음	4.8	구이	5.0	구이	5.1	장/ 양념	5.3	구이	5.4
7	장/ 양념	3.4	구이	3.3	구이	4.7	장/ 양념	4.9	장/ 양념	4.9	구이	5.2	장/ 양념	5.3
8	생채/ 무침	2.7	생채/ 무침	2.5	생채/ 무침	3.6	볶음	4.6	볶음	4.7	볶음	4.8	볶음	4.8
9	밥	2.5	장/ 양념	2.5	장/ 양념	3.5	생채/ 무침	2.9	생채/ 무침	3.0	장아찌 /절임	3.8	장아찌/ 절임	4.0
1 0	빵/과자	2.4	나물/ 숙채	2.2	나물/ 숙채	2.6	장아찌 /절임	2.4	장아찌 /절임	2.8	생채/ 무침	3.2	생채/ 무침	3.6

Song DY et al. Submitted


Food Sources of Na Intake KNHANES



Song DY et al. Submitted

Top Food Sources of Sodium in Other Countries

- UK
 - Cereal products (bread, other baked goods and breakfast cereals) ~ 38%.
 - Meat products (incl. processed meats) ~ 21%
- USA
 - Cereals and baked goods > 16%
 - Meat products incl. hot dogs and bacon >13%
- Japan
 - Soy sauce, salted vegetables and fruits, miso soup, fresh and salted fish and salt added
- China
 - Salt added and soy sauce



Epidemiologic Studies

DISTRIBUTION: DESCRIPTIVE STUDIES

DETERMINANTS: ANALYTIC STUDIES

- Correlational or ecologic study
- Cross-sectional study

Search for factors associated with or predictive of outcome

- Observational study
 - case-control
 - cohort
- Intervention study

 e.g. randomized clinical
 trial

Cross-sectional study

Sodium Intake Among People with Normal and High Blood Pressure

Umed A. Ajani, MBBS, MPH, Sandra B. Dunbar, RN, DSN, Earl S. Ford, MD, MPH, Ali H. Mokdad, PhD, George A. Mensah, MD

Table 2. Sodium intake (mg) among participants with normal and high blood pressure, NHANES 1999–2000							
	High blood pressure	No high blood pressure	p value*				
Sample size	1673	2338					
Weighted sample	58723759	$118\ 441\ 907$					
Mean	3330	3600					
Median	2987	3243					
Geometric mean	2885	3146	$<\!0.001$				
Adjusted geometric mean	2992	3089	0.032				

NHANES, National Health and Nutrion Examination Survey.

*Determined from log-transformed sodium intake.

Ajani UA Am J Prev Med 2005

Cross-sectional study


- Snapshot in time: information on exposure and outcome of individuals assessed simultaneously
- Time saving, data often available and regularly updated
- Limitations:

No temporal sequence, so ability to test hypothesis will depend on the exposure. If exposure cannot or unlikely to change as a result of the disease, could be hypothesis testing.

Analytic Study

- 1. Among individuals, with appropriate comparison group, with appropriate time sequence, and with adequate control of confounding.
- 2. Observational studies (exposures are self-selected)
 - Case-control
 - Cohort
- 3. Intervention studies (exposures are allocated by investigators)

e.g. randomized clinical trial




Case-control design:


STRENGTHS:

- Efficient in terms of time and money, since disease already occurred
- Efficient way to deal with long latent period
- Can examine effects of other risk factors

LIMITATIONS:

 Worried about ability to get accurate exposure information for right time period (1 year? 5 years? 10 years?) **Cohort Study: Selection into study on basis of exposure status**





Cohort design:

STRENGTHS:

- More accurate exposure information.
- Can elucidate temporal relationship (analysis by time).
- Can look at multiple outcomes

LIMITATIONS:

- Will take longer in time (latent period), and be more expensive.
- Need relevant data to be available
- Need to follow-up participants for long periods of time.


RESEARCH

Long term effects of dietary sodium reduction on cardiovascular disease outcomes: observational follow-up of the trials of hypertension prevention (TOHP)

BM


Nancy R Cook, associate professor,¹ Jeffrey A Cutler, former senior scientific adviser,² Eva Obarzanek, research nutritionist,² Julie E Buring, professor,¹ Kathryn M Rexrode, assistant professor of medicine,¹ Shiriki K Kumanyika, professor of epidemiology,³ Lawrence J Appel, professor of medicine,⁴ Paul K Whelton, president and chief executive officer,⁵ for the Trials of Hypertension Prevention Collaborative Research Group

TOHP study



• The first TOHP trial tested the feasibility and efficacy of seven non-pharmacological interventions in reducing blood pressure in people with high normal blood pressure.

 Interventions : weight loss, sodium reduction, stress management, and nutritional supplements (calcium, magnesium, potassium, and fish oil).



• The second TOHP trial tested the effects of weight loss and sodium reduction on incident hypertension and blood pressure.

• 2×2 factorial design \rightarrow effects of the sodium reduction intervention were analysed by grouping data for the 2 sodium reduction interventions (alone or with weight loss) and for the 2 non-sodium reduction groups (usual care or weight loss alone).

Follow up study

- The observational follow-up for cardiovascular disease began in 2000, and ended in 2004-5.
- Data on all events occurring since the end of the trials was collected by mail and phone.
- Information on self reported sodium intake was collected on the final follow-up questionnaire sent in 2004-5.

Table 1 | Characteristics of participants in TOHP I and II according to allocation to sodium reduction intervention or control group. Numbers are means (SDs) unless stated otherwise

		TOHP I		TOHP II*			
	Intervention (n=327)	Control (n=417)	P value	Intervention (n=1191)	Control(n=1191)	P value	
Baseline							
No (%) of men	232 (71.0)	299 (71.7)	0.82	784 (65.8)	782 (65.7)	0.93	
No (%) according to race:							
White	255 (78.0)	319 (76.5)	0.89	950 (79.8)	938 (78.8)	0.20	
Black	64 (19.6)	87 (20.9)		212 (17.8)	209 (17.6)		
Other	8 (2.4)	11 (2.6)		29 (2.4)	44 (3.7)	-	
Age (year)	43.4 (6.6)	42.6 (6.5)	0.074	43.9 (6.2)	43.3 (6.1)	0.015	
Weight (kg)	82.7 (14.3)	82.8 (13.9)	0.90	93.8 (14.3)	93.5 (13.8)	0.66	
BMI (kg/m²)	27.1 (3.8)	27.1 (3.6)	0.88	30.9 (3.1)	30.9 (3.1)	0.87	
SBP (mm Hg)	124.8 (8.5)	125.1 (8.1)	0.57	127.5 (6.6)	127.4 (6.2)	0.70	
DBP (mm Hg)	83.7 (2.7)	83.9 (2.8)	0.43	86.0 (1.9)	85.9 (1.9)	0.11	
Sodium excretion (mmol/24 h)	154.6 (59.9)	156.4 (60.5)	0.70	182.9 (78.4)	184.5 (76.8)	0.62	
Change to end of trial							
Change in weight (kg)	-0.2 (3.8)	0.2 (3.9)	0.19	0.7 (5.5)	0.8 (5.7)	0.67	
Change in sodium excretion (mmol/24 h)	<mark>-55.2 (76.9)</mark>	-11.3 (77.7)	<0.0001	-42.5 (89.0)	<mark>-9.8 (87.7)</mark>	<0.0001	

BMI=body mass index; SBP=systolic blood pressure; DBP=diastolic blood pressure.

*In TOHP II (a 2×2 factorial trial), participants were grouped according to whether they did or did not receive reduced sodium intervention. Hence, active sodium reduction group includes those assigned to sodium reduction alone and to sodium reduction plus weight loss, while control group includes those assigned to usual care.





Fig 2 | Cumulative incidence of cardiovascular disease (CVD) by sodium intervention group in TOHP I and II, adjusted for age, sex, and clinic

Fig 3 | Total mortality by sodium intervention group in TOHP I and II, adjusted for age, sex, and clinic

Dietary Salt Intake and Mortality in Patients With Type 2 Diabetes

- 638 patients attending a single diabetes clinic in Melbourne, Australia were followed in a prospective cohort study for a median of 9.9 years.
- Baseline sodium excretion was estimated from 24h urinary collections.
- 175 deaths, 75 (43%) of which were secondary to cardiovascular events.


Cumulative hazard (Nelson-Aalen) of all-cause mortality, stratified by percentiles (5th, 25th, 7 5th, and 95th) of 24-h urinary sodium excretion.




with 24-h urinary sodium excretion.

All-cause mortality

Intervention Study: Type of prospective cohort study in which exposure is allocated by investigator



DASH-sodium Reduced Sodium Intake and Hypertension



The Effect on Systolic Blood Pressure (Panel A) and Diastolic Blood Pressure (Panel B) of Reduced Sodium Intake and the DASH Diet

The reduction of sodium intake to levels below the current recommendation and the DASH diet both lower blood pressure substantially, with greater effects in combination than singly. Long-term health benefits will depend on the ability of people to make long-lasting dietary changes and the increased availability of lower-sodium foods.

Sacks FM et al. NEJM 2001

Intervention study:

STRENGTHS:

- True control of exposure (exercise pattern)
- Ability to control confounding

LIMITATIONS:

- Most expensive design, needs most resources
- Issues of compliance with regimen


Meta-analysis

- Quantitative review and synthesis of similar but independent studies
- Combine information over several studies
 to increase power and generalizeablility
- Estimate an average or pooled effect over studies
- Examine differences across studies to determine modification of treatment effect

Altered dietary salt intake for preventing and treating diabetic kidney disease (Review)

Suckling RJ, He FJ, MacGregor GA





Suckling RJ et al. 2010

SBP among Adults with Type 1 or 2 DM

Review: Altered dietary salt intake for preventing and treating diabetic kidney disease Comparison: 1 Net change with altering salt diet

Outcome: 1 Systolic BP

Study or subgroup	Mean Difference (SE)	Mean Difference IV,Fixed,95% CI	Weight	Mean Difference IV,Fixed,95% CI	
1 Long-term studies Dodson_P1989	-13 (6.5927)		1.7 %	-13.00 [-25.92, -0.08]	
Dodson_X 1989	-9.7 (4.2064)	— +—	4.1 %	-9.70[-17.94, -1.46]	
Houlihan_Losartan 200	2 -9.7 (3.8265)	+	4.9 %	-9.70[-17.20, -2.20]	
Houlihan_Placebo 2002	2 1.8 (3.9286)		4.7 %	1.80 [-5.90, 9.50]	
Mulhauser 1996	-4.9 (4.1837)		4.1 %	-4.90[-13.10, 3.30]	
Subtotal (95% Cl) Heterogeneity: Chi ² = 6.84 Test for overall effect: Z = 3	, df = 4 (P = 0.14); l ² =41% 3.22 (P = 0.0013)	•	19.4 %	-6.20 [-9.98, -2.43]	
2 Short-term studies Imanishi_Micro 2001	-11 (2.7613)		9.4 %	-11.00 [-16.41, -5.59]	
lmanishi_Normo 2001	-7 (4.6368)	-+	3.3 %	-7.00[-16.09, 2.09]	
Luik 2002	-3.1 (1.6)	-	28.1 %	-3.10 [-6.24, 0.04]	
Petrie 1998	2 (4.3554)	+	3.8 %	2.00 [-6.54, 10.54]	
Trevisan_Micro 1998	-4 (2)	-	18.0 %	-4.00 [-7.92, -0.08]	
Trevisan_Normo 1998	-17 (2)	+	18.0 %	-17.00[-20.92,-13.08]	
Subtotal (95% Cl) Heterogeneity: Chi ² = 39.4 Test for overall effect: Z = 3	9, df = 5 (P<0.00001); l² =8; 7.67 (P < 0.00001)	7%	80.6 %	-7.25 [-9.10, -5.40]	
Test for overall effect: Z = 1	6, df = 10 (P<0.00001); l ² =; 8.31 (P < 0.00001) ces: Chi ² = 0.24, df = 1 (P =		100.0 %	-7.04 [-8.71, -5.38]	
	-50 Favours low salt	-25 0 25 Favours hig	50 h salt		

Suckling RJ et al. 2010

DBP among Adults with Type 1 or 2 DM

Review: Altered dietary salt intake for preventing and treating diabetic kidney disease Comparison: 2 Net change in BP in type 1 and type 2 diabetes Outcome: 2 Diastolic BP

Study or subgroup	Mean Difference (SE)	Mean Difference IV,Fixed,95% CI	Weight	Mean Difference IV,Fixed,95% CI	
1 Type 1 diabetes Luik 2002	-1.4 (1.2)		15.2 %	-1.40 [-3.75, 0.95]	
Mulhauser 1996	-5.3 (2.1939)		4.6 %	-5.30[-9.60, -1.00]	
Trevisan_Micro 1998	-2 (1)		21.9 %	-2.00[-3.96, -0.04]	
Trevisan_Normo 1998	-5 (1)		21.9 %	-5.00 [-6.96, -3.04]	
Subtotal (95% Cl) Heterogeneity: Chi ² = 7.83 Test for overall effect: Z =	8, df = 3 (P = 0.05); l ² =629 5.33 (P < 0.00001)	↔	63.7 %	-3.13 [-4.28, -1.98]	
2 Type 2 diabetes Dodson_P 1989	-1.8 (3.4817)		1.8 %	-1.80 [-8.62, 5.02]	
Dodson_X 1989	-5.1 (2.9418)		2.5 %	-5.10[-10.87, 0.67]	
Houlihan_Losartan 200	2 -5.5 (1.4796)		10.0%	-5.50[-8.40,-2.60]	
Houlihan_Placebo 2003	2 3.3 (2.551)		3.4 %	3.30 [-1.70, 8.30]	
lmanishi_Micro 2001	-6 (1.5411)		9.2 %	-6.00[-9.02,-2.98]	
lmanishi_Normo 2001	0 (1.7678)		7.0 %	0.0 [-3.46, 3.46]	
Petrie 1998	5 (3.0929)		2.3 %	5.00 [-1.06, 11.06]	
Subtotal (95% Cl) Heterogeneity: Chi ² = 22.9 Test for overall effect: Z =	91, df = 6 (P = 0.00083); ² 3.69 (P = 0.00022)	=74%	36.3 %	-2.87 [-4.39, -1.35]	
Test for overall effect: Z =	81, df = 10 (P = 0.00063); 6.47 (P < 0.00001) ices: Chi² = 0.07, df = 1 (P		100.0 %	-3.03 [-3.95, -2.11]	
	-20 Favours low salt	-10 0 10 Favours hig	20 h salt		

Suckling RJ et al. 2010

Issues

•Complexity of diet

-Components are inter-correlated

-Exposure cannot be characterized as present or absent

–Within-person variation

-Measurement error

• Bias

-Confounding factor


-Treatment difference

-Compliance

Interaction

-Treatment


-Genetic factors (incl. sodium sensitivity)



Concentration or intake of nutrient

Hypothetical relationship between intake of an essential dietary factor and health.

Multiple Factors



Issues in Intervention Study

- Study design
 - Cross-over or Parallel design
 - Randomization vs. Non-randomization
 - Blind
- Participants
 - Illness
 - Age, gender, and other factors
- Level of sodium restriction
 - Compliance
 - Effect
 - Application
- Outcome
- Interaction
- Duration of study

Standards of Medical Care in Diabetes - 2012

 Lifestyle therapy for hypertension consists of weight loss, if overweight; Dietary Approaches to Stop Hypertension (DASH)-style dietary pattern, including reducing sodium and increasing potassium intake; moderation of alcohol intake; and increased physical activity. (B)

Although there are no well-controlled studies of diet and exercise in the treatment of hypertension in individuals with diabetes, the Dietary Approaches to Stop Hypertension (DASH) study in nondiabetic individuals has shown antihypertensive effects similar to pharmacologic monotherapy. Lifestyle therapy consists of reducing sodium intake (to <1,500 mg per day) and excess body weight; increasing consumption of fruits, vegetables (8–10 servings per day), and low-fat dairy products (2–3 servings per day); avoiding excessive alcohol consumption (no more than two servings per day in men and no more than one serving per day in women)

Sacks FM et al. NEJM 2001

대한당뇨병학회 진료지침 2011

 당뇨병성 합병증의 발생이나 진행의 지연을 위해서는 혈 당뿐만 아니라 혈압의 조절도 중요하므로 나트륨은 4000 mg 이내로 하며 고혈압이나 신장 합병증, 심혈관계 질환 을 동반한 경우에는 2000-3000 mg (소금 5-7.5 g) 이내로 제한하는 것이 중요하다.

Future Direction

•

.

Cross-Sectional Study

Prospective Study

Intervention Study

Clinical Implication

- Sodium intake status and morbidity among diabetic patients
- Prospective study of sodium intake or sodium excretion and mortality and morbidity among diabetic patients
- Effect of dietary modification and nutrition education on sodium reduction
- Effect of sodium reduction on mortality and morbidity of diabetic patients
- Sodium reduction strategy
- Korean-specific guidelines

Summary

- Research on dietary sodium intake and mortality and morbidity among patients with diabetes is sparse.
- Intervention studies in a clinical setting and further prospective studies of diabetic patients are warranted.

Acknowledgements

- 송다영
- 박종은
- 김영하